Dimension Therapeutics Announces Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Congress
October 11 2016 - 8:00AM
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company advancing novel, adeno-associated virus (AAV) gene
therapies targeting the liver, a key organ for human metabolism,
today announced poster presentations that will highlight advances
in mammalian vector manufacturing for the Company’s novel pipeline
of product candidates. The presentations will take place during the
upcoming ESGCT Congress, taking place in Florence, Italy, October
18-21, 2016.
“We are pleased that the ESCGT has chosen to highlight the
innovation supporting our current and next generation HELA 2.0 AAV
manufacturing platform,” said Dr. Annalisa Jenkins, MBBS, FRCP,
Chief Executive Officer of Dimension. “As an early clinical-stage
company, we continue to enhance our scientific platform, making
important progress most recently with the addition of our non-GMP
facility in Woburn, Massachusetts. We are committed every day to
innovation in the science and medicine of rare diseases associated
with the liver and in the delivery of a robust, sustainable quality
manufacturing platform.”
The poster presentation details are as follows:
Title: Establishing a clone selection strategy
to accelerate recombinant adeno-associated virus (rAAV) producer
cell line development (Poster #P368)Session Title:
Poster Session IISession Viewing Dates Include:
Thursday, October 20, 2016Location: Palazzo degli
Affari, Second Floor, Leonardo RoomAuthors:
Nicholas Richards1, Alix Eastham1, Aubrey R. Tiernan1, Vincent
Borowy1, K. Reed Clark1, Samuel C. Wadsworth1, Christopher Tipper1,
and Ying Jing1 1Dimension Therapeutics, Inc.
Title: Molecular assay toolbox to identify
characteristics of recombinant adeno-associated virus
(rAAV)-producing cell lines (Poster #P379)Session
Title: Poster Session ISession Viewing Dates
Include: Wednesday, October 19,
2016Location: Palazzo degli Affari, Second Floor,
Leonardo RoomAuthors: Aubrey R. Tiernan1, Nicholas
Richards1, Alix Eastham1, Vincent Borowy1, K. Reed Clark1, Samuel
C. Wadsworth1, and Christopher Tipper1 1Dimension
Therapeutics, Inc.
Title: Particle titer determination and
characterization of rAAV molecules using nanoparticle tracking
analysis and other techniques (Poster #P394)Session
Title: Poster Session IISession Viewing Dates
Include: Thursday, October 20,
2016Location: Palazzo degli Affari, Second Floor,
Leonardo RoomAuthors: Samantha F. Povlich1,
Jonathan G. Mehtala2, William Zolla1, Samuel C. Wadsworth1, K. Reed
Clark1, and Gwendolyn M. Wilmes1 1Dimension Therapeutics,
Inc.; 2Malvern Instruments
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in
discovering and developing new therapeutic products for people
living with devastating rare diseases associated with the liver,
based on the most advanced, mammalian adeno-associated virus (AAV)
gene delivery technology. Dimension is actively progressing its
broad pipeline, which features programs addressing unmet needs for
patients suffering from inherited metabolic diseases, including OTC
deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a
collaboration with Bayer in hemophilia A, and a wholly owned
clinical program in hemophilia B. The company targets diseases with
readily identifiable patient populations, highly predictive
preclinical models, and well-described, and often clinically
validated, biomarkers. Founded in 2013, Dimension maintains
headquarters in Cambridge, Massachusetts.
For more information, please visit
http://www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
development of new manufacturing processes, the anticipated
advantages of the new facility, increased production and scale
capacity, and growth in Dimension's portfolio. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risks that the benefits of new manufacturing processes will not
be realized; Dimension's product candidates, including its lead
candidate, DTX101, will not successfully be developed or
commercialized; and the risks described under the caption "Risk
Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q
for the quarter ended June 30, 2016, which is on file with the
Securities and Exchange Commission, as well as other risks detailed
in Dimension Therapeutics’ additional filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Dimension Therapeutics
undertakes no duty to update this information unless required by
law.
CONTACT:
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024